** Drugmaker Regeneron Pharmaceuticals' REGN.O shares fall 7% to $568 premarket

** Co posts Q1 adj. profit of $8.22/shr, missing analysts' estimates of $8.82, according to data compiled by LSEG

** Reports Q1 revenues of $3.03 billion vs estimates of $3.27 billion

** Says global sales for its blockbuster lung disease drug, Dupixent, rose 19% in Q1 to $3.67 billion

** However, U.S. sales of dry eye disease drugs Eylea and Eylea HD fell 26% to $1.4 billion

** "While we anticipated this may be a more messy quarter for Eylea due to ongoing funding concerns for patient assistance charities, other factors further exacerbated this dynamic" - Brokerage BMO Capital Markets

** As of last close, REGN has fallen 14.2% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))